---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-303051"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:29:06.789908+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio clears HSR waiting period for merger with Lenz Therapeutics on Dec. 21

## Summary
- HSR waiting period under Hart-Scott-Rodino Act expired at 11:59 p.m. ET on December 21, 2023.
- Merger with Lenz Therapeutics, previously announced Nov. 14, 2023, remains subject to stockholder approval and other conditions.
- Closing will result in Lenz becoming a wholly owned subsidiary of Graphite; combined company intends to list on Nasdaq.

## SEC filing metadata
- accession: 0001193125-23-303051
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000119312523303051/0001193125-23-303051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000119312523303051/d541575d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-303051
- JSON: https://secwatch.observer/filing/0001193125-23-303051.json
- Plain text: https://secwatch.observer/filing/0001193125-23-303051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.